Crizotinib and erlotinib inhibits growth of c-Met+/EGFRvIII+ primary human glioblastoma xenografts
Authors:
- 1 August 2018
- journal article
- research article
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 171, 26-33
Abstract
No abstract availableKeywords
Funding Information
- United Negro College Fund/Merck Science Initiative
- Neurosurgery Research and Education Foundation
- Burroughs Wellcome Fund
This publication has 25 references indexed in Scilit:
- Regulation of HGF Expression by ΔEGFR-Mediated c-Met Activation in Glioblastoma CellsNeoplasia, 2013
- Prospective, high-throughput molecular profiling of human gliomasJournal of Neuro-Oncology, 2012
- Establishment, Maintenance, and In Vitro and In Vivo Applications of Primary Human Glioblastoma Multiforme (GBM) Xenograft Models for Translational Biology Studies and Drug DiscoveryCurrent Protocols in Pharmacology, 2011
- Cyr61 Mediates Hepatocyte Growth Factor–Dependent Tumor Cell Growth, Migration, and Akt ActivationCancer Research, 2010
- Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiformeJournal of Neuro-Oncology, 2009
- Malignant astrocytic glioma: genetics, biology, and paths to treatmentGenes & Development, 2007
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Reactive Oxygen Species Mediate Met Receptor Transactivation by G Protein-coupled Receptors and the Epidermal Growth Factor Receptor in Human Carcinoma CellsJournal of Biological Chemistry, 2004
- In vivo targeting of SF/HGF and c‐met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosisThe FASEB Journal, 2001
- Epidermal Growth Factor Receptor Signaling Activates Met in Human Anaplastic Thyroid Carcinoma CellsExperimental Cell Research, 2000